Deflazacort - Marathon Pharmaceuticals

Drug Profile

Deflazacort - Marathon Pharmaceuticals

Alternative Names: 21 desacetyl DFZ prodrug; DFZ; Emflaza; MP-104

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Marathon Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Duchenne muscular dystrophy

Most Recent Events

  • 16 Mar 2017 PTC Therapeutics enters into an asset purchase agreement with Marathon Pharmaceuticals to acquire rights to Deflazacort
  • 09 Feb 2017 Registered for Duchenne muscular dystrophy (In adolescents, In children) in USA (PO, Suspension)
  • 09 Feb 2017 Registered for Duchenne muscular dystrophy (In adolescents, In children) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top